Novo Nordisk Aims for $23 Billion in 2035 Pipeline Sales

05:38 AM EDT, 09/21/2026 (MT Newswires) -- Novo Nordisk (NVO) on Monday outlined long-term financial and pipeline targets, including plans for 150 billion Danish kroner ($23.04 billion) in pipeline sales in 2035 and the launch of at least five multi-blockbusters by 2030. The Danish company said it is targeting compounded annual revenue growth rates from 2026 to 2030 in line with industry peers. Novo Nordisk aims to scale capacity to serve 10 times more people with obesity on oral GLP-1s and more than 60 million patients by 2030, it said. The drugmaker also said it envisions maintaining a "broadly stable" operating margin and an "attractive" dividend per share. Shares of the company were down 6% in recent premarket trading.